Krystal Biotech Analysts Boost Their Forecasts Following Upbeat Q1 Results

Benzinga Earnings

05/06

Krystal Biotech Inc (NASDAQ:KRYS) reported upbeat earnings for the first quarter on Monday.

The company posted quarterly earnings of $1.83 per share which beat the analyst consensus estimate of $1.39 per share. The company reported quarterly sales of $116.357 million which beat the analyst consensus estimate of $112.132 million.

“Following a successful 2025, we are entering 2026 with strong momentum, including two potential registrational study readouts and continued global expansion for VYJUVEK,” said Krish S. Krishnan, Chairman and Chief Executive Officer of Krystal Biotech. “With three pipeline products receiving platform designation, each development milestone strengthens the regulatory dataset, which could accelerate future programs and potentially reduce development risk. This compounding advantage underscores the value of the platform model we have been building since day one.”

Krystal Biotech shares fell 1% to trade at $284.01 on Tuesday.

These analysts made changes to their price targets on Krystal Biotech following earnings announcement.

Evercore ISI Group analyst Gavin Clark-Gartner maintained Krystal Biotech with an Outperform rating and raised the price target from $295 to $300.
Citigroup analyst Yigal Nochomovitz maintained the stock with a Buy and raised the price target from $371 to $378.

Considering buying KRYS stock? Here’s what analysts think:

Photo via Shutterstock

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2633940097"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2633940097\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2633940097?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 02:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2633940097","market":"us","top_or_hot":-1,"title":"Krystal Biotech Analysts Boost Their Forecasts Following Upbeat Q1 Results","media":"Benzinga Earnings","content":"<html><body><p><strong><a href=\"https://laohu8.com/S/KRYS\">Krystal Biotech</a> Inc</strong> (NASDAQ:KRYS) reported upbeat earnings for the first quarter on Monday.</p>\n<p>The company posted quarterly earnings of $1.83 per share which beat the analyst consensus estimate of $1.39 per share. The company reported quarterly sales of $116.357 million which beat the analyst consensus estimate of $112.132 million.</p>\n<p>“Following a successful 2025, we are entering 2026 with strong momentum, including two potential registrational study readouts and continued global expansion for VYJUVEK,” said Krish S. Krishnan, Chairman and Chief Executive Officer of Krystal Biotech. “With three pipeline products receiving platform designation, each development milestone strengthens the regulatory dataset, which could accelerate future programs and potentially reduce development risk. This compounding advantage underscores the value of the platform model we have been building since day one.”</p>\n<p>Krystal Biotech shares fell 1% to trade at $284.01 on Tuesday.</p>\n<p>These analysts made changes to their price targets on Krystal Biotech following earnings announcement.</p>\n<ul>\n<li><a href=\"https://laohu8.com/S/EVR\">Evercore</a> ISI Group analyst Gavin Clark-Gartner maintained Krystal Biotech with an Outperform rating and raised the price target from $295 to $300.</li>\n<li>Citigroup analyst Yigal Nochomovitz maintained the stock with a Buy and raised the price target from $371 to $378.</li>\n</ul>\n<p><strong>Considering buying KRYS stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"202\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/05141837/image-96-1024x202.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/05141837/image-96-1024x202.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/05141837/image-96-300x59.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/05141837/image-96-768x152.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/05141837/image-96.png 1265w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Krystal Biotech Analysts Boost Their Forecasts Following Upbeat Q1 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKrystal Biotech Analysts Boost Their Forecasts Following Upbeat Q1 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga Earnings </p>\n<p class=\"h-time\">2026-05-06 02:19</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><strong><a href=\"https://laohu8.com/S/KRYS\">Krystal Biotech</a> Inc</strong> (NASDAQ:KRYS) reported upbeat earnings for the first quarter on Monday.</p>\n<p>The company posted quarterly earnings of $1.83 per share which beat the analyst consensus estimate of $1.39 per share. The company reported quarterly sales of $116.357 million which beat the analyst consensus estimate of $112.132 million.</p>\n<p>“Following a successful 2025, we are entering 2026 with strong momentum, including two potential registrational study readouts and continued global expansion for VYJUVEK,” said Krish S. Krishnan, Chairman and Chief Executive Officer of Krystal Biotech. “With three pipeline products receiving platform designation, each development milestone strengthens the regulatory dataset, which could accelerate future programs and potentially reduce development risk. This compounding advantage underscores the value of the platform model we have been building since day one.”</p>\n<p>Krystal Biotech shares fell 1% to trade at $284.01 on Tuesday.</p>\n<p>These analysts made changes to their price targets on Krystal Biotech following earnings announcement.</p>\n<ul>\n<li><a href=\"https://laohu8.com/S/EVR\">Evercore</a> ISI Group analyst Gavin Clark-Gartner maintained Krystal Biotech with an Outperform rating and raised the price target from $295 to $300.</li>\n<li>Citigroup analyst Yigal Nochomovitz maintained the stock with a Buy and raised the price target from $371 to $378.</li>\n</ul>\n<p><strong>Considering buying KRYS stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"202\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/05141837/image-96-1024x202.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/05141837/image-96-1024x202.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/05141837/image-96-300x59.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/05141837/image-96-768x152.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/05141837/image-96.png 1265w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://www.benzinga.com/news/26/05/52297479/krystal-biotech-analysts-boost-their-forecasts-following-upbeat-q1-results","article_id":"2633940097","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2633940097","pubTimestamp":1778005196,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga Earnings","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"Krystal Biotech (KRYS) reported strong Q1 earnings, beating analyst estimates and with potential for future growth. Shares fell 1% on Tuesday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4588":"碎股","BK4581":"高盛持仓","KRYS":"Krystal Biotech Inc.","XBI":"SPDR S&P Biotech ETF"},"translate_title":"Krystal Biotech分析师在第一季度业绩乐观后上调了预测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KRYS":1,"XBI":1.5},"content_text":"Krystal Biotech Inc (NASDAQ:KRYS) reported upbeat earnings for the first quarter on Monday.\nThe company posted quarterly earnings of $1.83 per share which beat the analyst consensus estimate of $1.39 per share. The company reported quarterly sales of $116.357 million which beat the analyst consensus estimate of $112.132 million.\n“Following a successful 2025, we are entering 2026 with strong momentum, including two potential registrational study readouts and continued global expansion for VYJUVEK,” said Krish S. Krishnan, Chairman and Chief Executive Officer of Krystal Biotech. “With three pipeline products receiving platform designation, each development milestone strengthens the regulatory dataset, which could accelerate future programs and potentially reduce development risk. This compounding advantage underscores the value of the platform model we have been building since day one.”\nKrystal Biotech shares fell 1% to trade at $284.01 on Tuesday.\nThese analysts made changes to their price targets on Krystal Biotech following earnings announcement.\n\nEvercore ISI Group analyst Gavin Clark-Gartner maintained Krystal Biotech with an Outperform rating and raised the price target from $295 to $300.\nCitigroup analyst Yigal Nochomovitz maintained the stock with a Buy and raised the price target from $371 to $378.\n\nConsidering buying KRYS stock? Here’s what analysts think: \n\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}